The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyagawa, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyagawa, Y.

The Journal of Immunology, Vol 133, Issue 3 1270-1277, Copyright © 1984 by American Association of Immunologists


ARTICLES

Further characterization of IgM antibodies against maternal alloreactive T cells produced by cloned Epstein Barr virus-transformed cord B cells

Y Miyagawa

The mother obviously recognizes the fetus as an antigen, and the fetus is protected from the maternal immunologic attacks by eliciting anti- alloreactive T cell antibodies (T lymphocytotoxic human fetal antibody; TLFA). TLFA contains several antibodies against the maternal cells. It is thus necessary for further understanding of TLFA to obtain a single antibody from EBV-transformed cord B cells. EBV-transformations were performed in 28 cord B cell samples, and 16 cell lines were established. Antibody-binding assays of the cloned fetal IgM antibodies were performed by the respective maternal T cells grown in secondary mixed lymphocyte culture (MLC) stimulated by the paternal non-T cells and the maternal long-term culture killer T cells (LCT) in three different families. There were two types of cloned antibodies as identified by their binding to the respective maternal MLC responding T cells and the LCT. Their functions were further analyzed by the maternal MLC and lymphocytotoxic assays by using maternal-paternal cell combinations from the three families. One type of antibody inhibited the maternal MLC T cell proliferation (% inhibition: up to 28.2%, p less than 0.01), and the other inhibited the killer activity of the maternal LCT (% inhibition: up to 45.2%, p less than 0.001). Such a fetomaternal interaction bears perhaps on the fundamental mechanism whereby the mother does not reject the fetus.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1984 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1984 by The American Association of Immunologists, Inc. All rights reserved.